Advanced Healthcare Materials
April 8, 2023
Jing Ge, Ronghua Tan, Qian Gao et al.
Ketamine (KA), commonly used as an anesthetic, is now widely studied as an antidepressant for the treatment of depression. However, due to its side effects, such as addiction and cognitive impairment, the dosage and frequency of (S)‐ketamine approved by the FDA for the treatment of refractory depression is very low, which limits its efficacy. Here, a new multifunctional nanocarrier system...
International Journal of Health Sciences
April 5, 2023
Luísa Soares Capa, Gabrielle Simon Tronco, Virginia Nascimento Reinert et al.
: Treatment-resistant depression is a common psychiatric disorder that can lead to significant disability and decreased quality of life for patients. In recent years, there has been growing interest in the combination of intravenous ketamine and electroconvulsive therapy (ECT) for the treatment of treatment-resistant depression. Ketamine is an anesthetic that is an N-methyl-D-aspartate (NMDA)...
The Journal of Clinical Psychiatry
April 5, 2023
Albert Yeung, Guy Sapirstein, Laura D Crain et al.
Although consensus in the field is lacking, the most common definition for treatment-resistant depression (TRD) requires a minimum of 2 prior treatment failures with confirmed adequate dose and duration. This article presents a clinical example of TRD in a patient with a long history of depression and inadequate response to treatment. The prominent feature is the patient's persistent...
Current Psychology
April 1, 2023
Alan Maddock, Carolyn Blair
Abstract: This study aimed to systematically review studies which conducted a controlled mediation analysis in order to examine the potential mechanisms which underlie mindfulness-based programme’s (MBPs) effects on anxiety, depression and psychological distress in any health or mental health population. Searches of six databases (Medline (Ovid), PsycINFO, Cochrane Central Register of...
Mindfulness
April 1, 2023
Isa Zappullo, Vincenzo Paolo Senese, Roberta Cecere et al.
Abstract: Objectives: Available data suggest that inflexible allocation of attention in people on the autism spectrum can lead to anxiety and depression symptoms, through the increase of repetitive negative thinking (worry and rumination). In the present study, we used dispositional mindfulness as a proxy to attention flexibility and tested its role in the influence of repetitive negative...
Mindfulness
April 1, 2023
Stella Kümmerle, Thomas Heidenreich, Meike Müller-Engelmann
Abstract Objectives Despite various methodological concerns, previous studies mainly use questionnaires to assess mindfulness. Following a multi-measurement approach, the present study aimed to evaluate the added value of an experience-sampling measure in the context of posttraumatic stress disorder (PTSD) and depression. Method Data were collected in a PTSD group, depression group, and control...
CNS Spectrums
April 1, 2023
Amanda Jones, Caroline Streicher, Shawn Alter et al.
AbstractBackgroundAXS-05 (dextromethorphan-bupropion) is a novel, oral, investigational, NMDA receptor antagonist with multimodal activity being developed for MDD. The dextromethorphan component of AXS-05 is an NMDA receptor antagonist and a sigma-1 receptor agonist. The bupropion component of AXS-05 serves primarily to increase the bioavailability of dextromethorphan.MethodsAXS-05 was...
CNS Spectrums
April 1, 2023
Amanda Jones, Roger S McIntyre, Mark Jacobsen et al.
AbstractBackgroundTreatments for MDD that can improve both overall depressive and anhedonic symptoms are urgently needed.AXS-05 (dextromethorphan-bupropion) is a novel, oral, investigational NMDA receptor antagonist with multimodal activity being developed for MDD. The dextromethorphan component of AXS-05 is an NMDA receptor antagonist and a sigma-1 receptor agonist. The bupropion component of...
AJN, American Journal of Nursing
April 1, 2023
Diane S Aschenbrenner
Auvelity, an extended-release fixed combination of dextromethorphan and bupropion, is approved for the treatment of major depressive disorder in adults.Like all antidepressants, dextromethorphan-bupropion carries a boxed warning that it may increase the risk of suicidal thoughts and behaviors in pediatric and young adult patients. Seizures can also occur and are more likely at higher doses.The...
Journal of Affective Disorders
April 1, 2023
Olivier Payette, Paul Lespérance, V. D. Jodoin et al.
7 citations
BACKGROUND For individuals with treatment-resistant depression (TRD), transcranial magnetic stimulation (TMS) has become a well-established approach. In the past decade, intravenous (IV) racemic ketamine has also emerged as a potential treatment for TRD. Currently, little data is available on the clinical effects of IV racemic ketamine in TRD patients who experienced TMS-failure. METHODS...